Vyora Wellness Review
Best for: patients wanting coaching-inclusive compounded GLP-1 programs
Vyora Wellness offers compounded semaglutide ($299/mo) and compounded tirzepatide ($399/mo) as 4-week subscription plans. LegitScript certified. Price includes GLP-1 nutritional guidance, 24/7 coaching, and community access. BMI 25+ required.
Medium confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Vyora Wellness is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide (4-week) | compounded | $299 |
| Compounded Tirzepatide (4-week) | compounded | $399 |
✓ Pros
- •LegitScript certified
- •Price includes nutritional guidance, 24/7 coaching, and community access
- •Both semaglutide and tirzepatide available
- •BMI 25+ eligibility threshold (lower than some competitors)
✗ Cons
- •State availability not publicly disclosed
- •Pricing is above average ($299–$399/mo) compared to competitors
- •Compounded only — no brand-name options
- •Broader platform (metabolic, longevity, topical products)
Ready to start with Vyora Wellness?
Starting at $299/month. See current pricing and start your free consultation.
Sources & methodology
Our Vyora Wellness review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Vyora Wellness
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Vyora Wellness?
Starting at $299/month. See current pricing and start your free consultation.